½ÃÀ庸°í¼­
»óǰÄÚµå
1467654

Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú ½ÃÀå º¸°í¼­ : ÀûÀÀÁõ, Á¦Ç°, ¼ºº°, ¿¬·É, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Endovascular Aneurysm Repair Market Report by Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Others), Product, Gender, Age, End-User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú ½ÃÀå ±Ô¸ð´Â 2023³â 30¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024-2032³â 4.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â±îÁö 43¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

µ¿¸Æ·ù´Â µ¿¸Æº®ÀÌ ¾àÈ­µÇ°Å³ª º¯¼ºµÇ¾î µ¿¸Æº®ÀÌ È®ÀåµÇ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. µ¿¸Æ·ù´Â ÀϹÝÀûÀ¸·Î ´ã¹è ¼Òºñ ¹× Èí¿¬°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µ¿¸Æ·ùÀÇ À¯º´·üÀº Á׻󵿸ưæÈ­Áõ, °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ, °áÇÕÁ¶Á÷ Àå¾Ö¿Í °°Àº ÁúȯÀ» °¡Áø »ç¶÷µéµµ µ¿¸Æ·ùÀÇ À¯º´·üÀÌ ³ô½À´Ï´Ù. Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú(EVAR)Àº ÀÌ·¯ÇÑ µ¿¸Æ·ù¸¦ Ä¡·áÇϱâ À§ÇØ ½ÃÇàµÇ´Â ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú ¶Ç´Â ¼ö¼ú·Î, µ¿¸Æ·ùÀÇ ¾àÇÑ ºÎÀ§¿¡ ÄÚÆÃµÈ ½ºÅÙÆ®(õÃþÀÌ ÀÖ´Â ±Ý¼Ó ¸Þ½¬ Æ©ºê)¸¦ »ðÀÔÇÏ¿© µ¿¸Æ·ù¸¦ Ä¡·áÇÏ´Â ¼ö¼úÀÔ´Ï´Ù. À̸¦ ÅëÇØ Ç÷¾×ÀÌ ºÎÇ®¾î ¿À¸¥ ºÎÀ§¿¡ °íÀÌÁö ¾Ê°í Èê·¯°¥ ¼ö ÀÖ´Â Åë·Î¸¦ È®º¸ÇØ ÆÄ¿­À» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç µ¿¸Æ·ù Ä¡·á¿¡ »ç¿ëµÇ´Â ¿©·¯ °¡Áö ±â±¸°¡ ½ÃÆÇµÇ°í ÀÖ½À´Ï´Ù.

EVAR Ä¡·á´Â ¼ö¼úÀ» ÇÒ Çʿ䰡 ¾ø±â ¶§¹®¿¡ ±âÁ¸ Ä¡·á¹ýº¸´Ù »ó´ëÀûÀ¸·Î ¾ÈÀüÇÕ´Ï´Ù. °á°úÀûÀ¸·Î ÀÌ ½Ã¼úÀº ÀÔ¿ø ±â°£ÀÌ Âª°í ȸº¹ÀÌ ºü¸¨´Ï´Ù. µ¿¸Æ·ùÀÇ À¯º´·ü°ú ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ Ç÷°ü ³» Ä¡·á´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ Á¡Á¡ ´õ ¸¹ÀÌ Ã¤ÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ ½Ã¼úÀÇ ÀáÀçÀû ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è Á¤ºÎ´Â ºñ¿ë ±¸Á¶¸¦ °³¼±Çϰí ȯÀڵ鿡°Ô EVAR Àåºñ ¹× Ä¡·á¹ýÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ ¿©·¯ ÇÁ·Î±×·¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÇ·á ±â°üÀº ´õ ºü¸¥ ȸº¹°ú ÇÕº´ÁõÀÌ ÀûÀº EVAR Àåºñ¿Í ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ªÀº ·£µù Á¸¿¡¼­ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ°í µ¿¸Æ °î·ü¿¡ ´ëÇÑ ÀûÇÕ¼ºÀ» Çâ»ó½ÃŰ´Â °³¼±µÈ ÀÌ½Ä ±â¼úÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº EVAR ¼ö¼úÀÇ ¼º°ø·üÀ» ´õ¿í ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

  • ¼¼°è Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ¿Ô°í, ¾ÕÀ¸·Î ¾î¶»°Ô ¼ºÀåÇÒ °ÍÀΰ¡?
  • ÀÌ »ê¾÷ÀÇ ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • COVID-19°¡ Àü ¼¼°è Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ÀûÀÀÁõº° ½ÃÀå ÇöȲÀº?
  • Á¦Ç°º° ½ÃÀå ºÐ¼®Àº?
  • ¼ºº°¿¡ µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • ¿¬·É´ëº° ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
  • »ê¾÷ ±¸Á¶¿Í ÁÖ¿ä ÁøÃâ ±â¾÷Àº?
  • ¾÷°èÀÇ °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú ¼¼°è ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ³»¿ª : ÀûÀÀÁõº°
  • ½ÃÀå ³»¿ª : Á¦Ç°º°
  • ½ÃÀå ³»¿ª : ¼ºº°
  • ½ÃÀå ³»¿ª : ¿¬·Éº°
  • ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀå ³»¿ª : Áö¿ªº°
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ÀûÀÀÁõº°

  • º¹ºÎ ´ëµ¿¸Æ·ù(AAA)
  • ÈäºÎ ´ëµ¿¸Æ·ù(TAA)
  • È亹ºÎ ´ëµ¿¸Æ·ù(TAAA)
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • °æÇÇÀû EVAR
  • Ã¥Àå EVAR
  • ´ëµ¿¸Æ ½ºÅÙÆ®¿Í TAA ±×·¡ÇÁÆ®
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ¼ºº°

  • ³²¼º
  • ¿©¼º

Á¦9Àå ½ÃÀå ³»¿ª : ¿¬·Éº°

  • ¼Ò¾Æ
  • ¼ºÀÎ
  • °í·ÉÀÚ

Á¦10Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦11Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • À¯·´
  • ºÏ¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«

Á¦12Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °¡°Ý ºÐ¼®

Á¦16Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Medtronic plc
    • Cook Group Incorporated
    • W. L. Gore & Associates, Inc.
    • Bolton Medical, Inc.
    • Gamida Cell Ltd.
    • JOTEC GmbH
    • Getinge AB(Maquet)
    • Shanghai MicroPort Medical(Group) Co., Ltd.
    • Terumo Corporation
    • Endologix, Inc.
    • Lombard Medical Limited
    • Cardinal Health, Inc.
ksm 24.05.03

The global endovascular aneurysm repair (EVAR) market size reached US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

An aneurysm refers to the enlargement of the arterial wall due to weakness or degeneration. It is generally associated with tobacco consumption and smoking. The prevalence of aneurysms is also higher among people with medical conditions such as atherosclerosis, high cholesterol levels, and connective tissue disorder. Endovascular aneurysm repair (EVAR) refers to a minimally invasive procedure or surgery that is performed to repair these aneurysms. EVAR procedure is performed by inserting a covered stent, a metal mesh tube with a layer of fabric, into the weak area of the artery. This provides a route for the blood to flow without accumulating in the bulge and prevents it from bursting. Nowadays, multiple devices are available in the market that are used to treat aneurysms.

The EVAR treatment is comparatively safer than traditional procedures, as there is no need for performing surgery. As a result, this technique results in short hospital stays and quicker recovery. Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers. This has further been supported by the rising awareness of the potential benefits of the procedure. Also, governments across the globe are undertaking several programs to improve the cost structure and spread awareness about the availability of EVAR devices and treatment procedures among patients. In line with this, healthcare institutions are developing EVAR devices and technologies that offer faster recovery and fewer complications. For instance, enhanced graft technologies have been created, which allow treatments with short landing zones and improve conformability to the artery curvature. These technologies have further helped in increasing the success rate of EVAR procedures.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global endovascular aneurysm repair (EVAR) market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication, product, gender, age and end-user.

Breakup by Indication:

Abdominal Aortic Aneurysm (AAA)

Thoracic Aortic Aneurysm (TAA)

Thoracoabdominal Aortic Aneurysm (TAAA)

Others

Breakup by Product:

Percutaneous EVAR

Fenestrated EVAR

Aortic Stents and TAA Grafts

Others

Breakup by Gender:

Male

Female

Breakup by Age:

Pediatric

Adult

Geriatric

Breakup by End-User:

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Breakup by Region:

Asia Pacific

Europe

North America

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc.

Key Questions Answered in This Report:

  • How has the global endovascular aneurysm repair market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the industry?
  • What has been the impact of COVID-19 on the global endovascular aneurysm repair industry?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the gender?
  • What is the breakup of the market based on the age?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the industry and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Endovascular Aneurysm Repair Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Product
  • 5.6 Market Breakup by Gender
  • 5.7 Market Breakup by Age
  • 5.8 Market Breakup by End-User
  • 5.9 Market Breakup by Region
  • 5.10 Market Forecast

6 Market Breakup by Indication

  • 6.1 Abdominal Aortic Aneurysm (AAA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Thoracic Aortic Aneurysm (TAA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Thoracoabdominal Aortic Aneurysm (TAAA)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Percutaneous EVAR
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Fenestrated EVAR
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Aortic Stents and TAA Grafts
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Gender

  • 8.1 Male
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Female
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Age

  • 9.1 Pediatric
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adult
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Geriatric
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Ambulatory Surgical Centers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 Asia Pacific
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Europe
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 North America
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Middle East and Africa
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast
  • 11.5 Latin America
    • 11.5.1 Market Trends
    • 11.5.2 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porter's Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Medtronic plc
    • 16.3.2 Cook Group Incorporated
    • 16.3.3 W. L. Gore & Associates, Inc.
    • 16.3.4 Bolton Medical, Inc.
    • 16.3.5 Gamida Cell Ltd.
    • 16.3.6 JOTEC GmbH
    • 16.3.7 Getinge AB (Maquet)
    • 16.3.8 Shanghai MicroPort Medical (Group) Co., Ltd.
    • 16.3.9 Terumo Corporation
    • 16.3.10 Endologix, Inc.
    • 16.3.11 Lombard Medical Limited
    • 16.3.12 Cardinal Health, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦